Blog

The nurse knows the best time to implement a teaching plan is when

A nurse notices a trend in patient falls on a specific unit. Using the hospital’s electronic health record (EHR) system, what is the best informatics-based action to take?

A young toddler is going to have surgery on the right ear. Which teaching method is most appropriate for this developmental stage?

The nurse manager wants to determine the cause of an increase in medication errors over the past 6 months. This is an example of which type of research?

Which of the following is an example of direct research utilization?

Two bottled-water manufacturers, A and G, are competing in a Bertrand pricing setting with differentiated products.  The demand for A’s products is given by:

Innovation investment will increase if:

Consider a hospital debating whether it should adopt advanced Electronic Medical Records (EMR) technology, or stay with its current setup. Adoption of advanced EMR will incur a short term cost, but is expected to improve future payoffs for the hospital. How can adoption of EMR technology improve hospital payoffs? “Hospitals … can better consolidate information through the digitalization of data, which helps health-care providers to store, retrieve, and examine these data more efficiently… help hospitals to improve health-care quality further by providing physicians with effective decision support and easy care coordination.” (Wang 2022 IER, “Competition and multilevel technology adoption”). Suppose the hospital is forecasting 4 years ahead. Its stream of profits from each decision is given below, where t = 0 denotes current year. t = 0 t = 1 t = 2 t = 3 t = 4 Current tech 5000 4000 3000 2000 500 Upgrade to advanced tech -3000 6000 5000 5000 4000   Let PDV denote “present discounted value”. The interest rate is 5%, so r = 0.05. What is the PDV from staying at current tech? [a1] What is the PDV from upgrading to advanced tech? [a2] Should the firm upgrade? (Type in “Yes” or “No”) [a3]

An acquisition of an up-and-coming biotech firm by a large pharmaceutical incumbent must be anticompetitive.

Consider a model of monopolistic competition where an incumbent has a constant marginal cost of MC. For this firm, the long-run equilibrium price P is such that P > MC.